Xilis, Inc., a pioneering company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today the presentation of data on the company’s proprietary MOS technology. Data were presented at the 2021 European Society for Medical Oncology (ESMO) Congress in an oral presentation and two poster presentations.
“There is a significant unmet need for a patient-derived microtumor platform that captures the entire microenvironment and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “In these three presentations, we provide evidence that our MOS technology retains the same characteristics as patient samples and has the capability to quickly evaluate cancer drug response. Our platform can support pharmaceutical companies in accelerating drug discovery and development and is being developed to help clinicians make more informed treatment decisions.”